Morfin-Otero Rayo, Garza-Gonzalez Elvira, Aguirre-Diaz Sara A, Escobedo-Sanchez Rodrigo, Esparza-Ahumada Sergio, Perez-Gomez Hector R, Petersen-Morfin Santiago, Gonzalez-Diaz Esteban, Martinez-Melendez Adrian, Rodriguez-Noriega Eduardo
Hospital Civil de Guadalajara, Fray Antonio Alcalde, Mexico; Instituto de Patología Infecciosa y Experimental, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Mexico.
Servicio de Gastroenterología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Mexico; Departamento de Patología Clínica, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Mexico.
Braz J Infect Dis. 2016 Jan-Feb;20(1):8-13. doi: 10.1016/j.bjid.2015.09.008. Epub 2015 Nov 24.
Clostridium difficile infections caused by the NAP1/B1/027 strain are more severe, difficult to treat, and frequently associated with relapses.
A case-control study was designed to examine a C. difficile infection (CDI) outbreak over a 12-month period in a Mexican hospital. The diagnosis of toxigenic CDI was confirmed by real-time polymerase chain reaction, PCR (Cepheid Xpert C. difficile/Epi).
During the study period, 288 adult patients were evaluated and 79 (27.4%) patients had confirmed CDI (PCR positive). C. difficile strain NAP1/B1/027 was identified in 31 (39%) of the patients with confirmed CDI (240 controls were included). Significant risk factors for CDI included any underlying disease (p<0.001), prior hospitalization (p<0.001), and antibiotic (p<0.050) or steroid (p<0.001) use. Laboratory abnormalities included leukocytosis (p<0.001) and low serum albumin levels (p<0.002). Attributable mortality was 5%. Relapses occurred in 10% of patients. Risk factors for C. difficile NAP1/B1/027 strain infections included prior use of quinolones (p<0.03). Risk factors for CDI caused by non-027 strains included chronic cardiac disease (p<0.05), chronic renal disease (p<0.009), and elevated serum creatinine levels (p<0.003). Deaths and relapses were most frequent in the 027 group (10% and 19%, respectively).
C. difficile NAP1/BI/027 strain and non-027 strains are established pathogens in our hospital. Accordingly, surveillance of C. difficile infections is now part of our nosocomial prevention program.
由NAP1/B1/027菌株引起的艰难梭菌感染更为严重,难以治疗,且常与复发相关。
设计了一项病例对照研究,以调查墨西哥一家医院在12个月期间的艰难梭菌感染(CDI)暴发情况。产毒型CDI的诊断通过实时聚合酶链反应(PCR)(赛沛Xpert艰难梭菌/疫情检测)得以确认。
在研究期间,对288名成年患者进行了评估,79名(27.4%)患者确诊为CDI(PCR阳性)。在确诊为CDI的患者中有31名(39%)鉴定出艰难梭菌菌株NAP1/B1/027(纳入了240名对照)。CDI的显著危险因素包括任何基础疾病(p<0.001)、既往住院史(p<0.001)以及使用抗生素(p<0.050)或类固醇(p<0.001)。实验室异常包括白细胞增多(p<0.001)和血清白蛋白水平降低(p<0.002)。归因死亡率为5%。10%的患者出现复发。艰难梭菌NAP1/B1/027菌株感染的危险因素包括既往使用喹诺酮类药物(p<0.03)。非027菌株引起的CDI的危险因素包括慢性心脏病(p<0.05)、慢性肾病(p<0.009)以及血清肌酐水平升高(p<0.003)。死亡和复发在027组最为常见(分别为10%和19%)。
艰难梭菌NAP1/BI/027菌株和非027菌株是我院已确定的病原体。因此,艰难梭菌感染的监测现已成为我们医院感染预防计划的一部分。